Peritransplantation Use of Ruxolitinib in Myelofibrosis

Uroosa Ibrahim; Giulia Eva Maria Petrone; John Mascarenhas; Alla Keyzner

doi:10.1016/j.bbmt.2020.08.015

Peritransplantation Use of Ruxolitinib in Myelofibrosis

Biol Blood Marrow Transplant. 2020 Dec;26(12):2177-2180. doi: 10.1016/j.bbmt.2020.08.015. Epub 2020 Aug 18.

Authors

Uroosa Ibrahim¹, Giulia Eva Maria Petrone², John Mascarenhas², Alla Keyzner²

Affiliations

¹ Tisch Cancer Institute, Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: [email protected].
² Tisch Cancer Institute, Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.

PMID: 32818555
DOI: 10.1016/j.bbmt.2020.08.015

Abstract

Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.

Keywords: Allogeneic transplant; HSCT; Myelofibrosis; Ruxolitinib.

Publication types

Review

MeSH terms

Hematopoietic Stem Cell Transplantation*
Humans
Nitriles
Primary Myelofibrosis* / drug therapy
Protein Kinase Inhibitors / therapeutic use
Pyrazoles / therapeutic use
Pyrimidines

Substances

Nitriles
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ruxolitinib